Jansen B - Search Results

1

Small interfering RNA targeting bcl-2 sensitizes malignant melanoma.

Wacheck V, Losert D, Günsberg P, Vornlocher HP, Hadwiger P, Geick A, Pehamberger H, Müller M, Jansen B. Wacheck V, et al. Among authors: jansen b. Oligonucleotides. 2003;13(5):393-400. doi: 10.1089/154545703322617078. Oligonucleotides. 2003. PMID: 15000830

2

Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy.

Heere-Ress E, Thallinger C, Lucas T, Schlagbauer-Wadl H, Wacheck V, Monia BP, Wolff K, Pehamberger H, Jansen B. Heere-Ress E, et al. Among authors: jansen b. Int J Cancer. 2002 May 1;99(1):29-34. doi: 10.1002/ijc.10248. Int J Cancer. 2002. PMID: 11948488 Free article.

3

Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.

Thallinger C, Wolschek MF, Wacheck V, Maierhofer H, Günsberg P, Polterauer P, Pehamberger H, Monia BP, Selzer E, Wolff K, Jansen B. Thallinger C, et al. Among authors: jansen b. J Invest Dermatol. 2003 Jun;120(6):1081-6. doi: 10.1046/j.1523-1747.2003.12252.x. J Invest Dermatol. 2003. PMID: 12787138 Free article.

4

Bcl-xL antisense oligonucleotides chemosensitize human glioblastoma cells.

Guensberg P, Wacheck V, Lucas T, Monia B, Pehamberger H, Eichler HG, Jansen B. Guensberg P, et al. Among authors: jansen b. Chemotherapy. 2002 Sep;48(4):189-95. doi: 10.1159/000063873. Chemotherapy. 2002. PMID: 12218266

5

Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo.

Halaschek-Wiener J, Kloog Y, Wacheck V, Jansen B. Halaschek-Wiener J, et al. Among authors: jansen b. J Invest Dermatol. 2003 Jan;120(1):109-15. doi: 10.1046/j.1523-1747.2003.12009.x. J Invest Dermatol. 2003. PMID: 12535206 Free article.

6

Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice.

Wacheck V, Krepler C, Strommer S, Heere-Ress E, Klem R, Pehamberger H, Eichler HG, Jansen B. Wacheck V, et al. Among authors: jansen b. Antisense Nucleic Acid Drug Dev. 2002 Dec;12(6):359-67. doi: 10.1089/108729002321082438. Antisense Nucleic Acid Drug Dev. 2002. PMID: 12568310

7

Betulinic acid-induced Mcl-1 expression in human melanoma--mode of action and functional significance.

Selzer E, Thallinger C, Hoeller C, Oberkleiner P, Wacheck V, Pehamberger H, Jansen B. Selzer E, et al. Among authors: jansen b. Mol Med. 2002 Dec;8(12):877-84. Mol Med. 2002. PMID: 12606824 Free PMC article.

8

CpG oligonucleotides elicit antitumor responses in a human melanoma NOD/SCID xenotransplantation model.

Krepler C, Wacheck V, Strommer S, Hartmann G, Polterauer P, Wolff K, Pehamberger H, Jansen B. Krepler C, et al. Among authors: jansen b. J Invest Dermatol. 2004 Feb;122(2):387-91. doi: 10.1046/j.0022-202X.2004.22202.x. J Invest Dermatol. 2004. PMID: 15009720 Free article.

9

Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.

Thallinger C, Wolschek MF, Maierhofer H, Skvara H, Pehamberger H, Monia BP, Jansen B, Wacheck V, Selzer E. Thallinger C, et al. Among authors: jansen b. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4185-91. doi: 10.1158/1078-0432.CCR-03-0774. Clin Cancer Res. 2004. PMID: 15217956

10

Pegylated and conventional interferon-alpha induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma SCID mouse xenotransplantation model.

Krepler C, Certa U, Wacheck V, Jansen B, Wolff K, Pehamberger H. Krepler C, et al. Among authors: jansen b. J Invest Dermatol. 2004 Oct;123(4):664-9. doi: 10.1111/j.0022-202X.2004.23433.x. J Invest Dermatol. 2004. PMID: 15373770 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

685 results

Search Page